Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Terremoto Biosciences Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07109726CT.gov A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Squamous Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fulvestrant (this asset) | Terremoto Biosciences Inc. | P1/2 | CCC · 48 |
| Cis-Diamminedichloroplatinum Ii | Qilu Hospital of Shandong University | P4 | BBB |
| Carboplatin | zhang yi | P3 | BBB |
| Docetaxel | Shanghai JMT-Bio Inc. | P3 | BBB |
| Cyclophosphamide | UNC Lineberger Comprehensive Cancer Center | P3 | BB |
| Gefitinib | Seoul Veterans Hospital | P3 | BB |
| Etoposide | Barbara Ann Karmanos Cancer Institute | P3 | BB |
| Atezolizumab | Imugene Limited | P3 | BB |
| Veliparib | AbbVie | P3 | BB |
+42 more in the Squamous Cell Lung Carcinoma cohort
Other indications for Fulvestrant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BB · 70 |
| Breast Cancer | — | P4 | BB · 69 |
| Invasive Breast Carcinoma | — | P2 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fulvestrant in Squamous Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fulvestrant-squamous-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →